| 出版应用/物种/样本/稀释 | 参考文献 |
|---|
| Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber J, et al. LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair. Clin Transl Med. 2021;11:e341 pubmed 出版商 |
- 免疫印迹基因敲除验证; 小鼠; 1:2000; 图 s1a
- 免疫印迹; 小鼠; 1:2000; 图 s1a
| Kluss J, Conti M, Kaganovich A, Beilina A, Melrose H, Cookson M, et al. Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity. NPJ Parkinsons Dis. 2018;4:13 pubmed 出版商 |
| Speidel A, Felk S, Reinhardt P, Sterneckert J, Gillardon F. Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells. PLoS ONE. 2016;11:e0165949 pubmed 出版商 |
| Schwab A, Ebert A. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation. Stem Cell Reports. 2015;5:1039-1052 pubmed 出版商 |
| Ho D, Kim H, Kim J, Sim H, Ahn H, Kim J, et al. Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression. Mol Brain. 2015;8:54 pubmed 出版商 |
| Choi I, Kim B, Byun J, Baik S, Huh Y, Kim J, et al. LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nat Commun. 2015;6:8255 pubmed 出版商 |
| Ysselstein D, Nguyen M, Young T, Severino A, Schwake M, Merchant K, et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients. Nat Commun. 2019;10:5570 pubmed 出版商 |
| Henderson M, Sengupta M, McGeary I, Zhang B, Olufemi M, Brown H, et al. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice. Acta Neuropathol Commun. 2019;7:28 pubmed 出版商 |
| Jang J, Oh H, Nam D, Seol W, Seo M, Park S, et al. Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity. Anim Cells Syst (Seoul). 2018;22:273-280 pubmed 出版商 |
| Henderson M, Peng C, Trojanowski J, Lee V. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. Acta Neuropathol Commun. 2018;6:45 pubmed 出版商 |
| Madero Pérez J, Fdez E, Fernández B, Lara Ordóñez A, Blanca Ramírez M, Gomez Suaga P, et al. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation. Mol Neurodegener. 2018;13:3 pubmed 出版商 |
| Chia R, Haddock S, Beilina A, Rudenko I, Mamais A, Kaganovich A, et al. Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7. Nat Commun. 2014;5:5827 pubmed 出版商 |
| Longo F, Russo I, Shimshek D, Greggio E, Morari M. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiol Dis. 2014;71:62-73 pubmed 出版商 |
